Signaling Pathway Map

Research Area

  • Inhibitory Selectivity
  • Solubility
Catalog No. Product Name Solubility(25°C)
Water DMSO Alcohol
S6003 Ataluren (PTC124) <1 mg/mL 57 mg/mL <1 mg/mL
S7139 CFTRinh-172 <1 mg/mL 82 mg/mL <1 mg/mL
S7329 IOWH032 <1 mg/mL 100 mg/mL <1 mg/mL
S8094 GlyH-101 <1 mg/mL 98 mg/mL <1 mg/mL
S1144 Ivacaftor (VX-770) <1 mg/mL 78 mg/mL <1 mg/mL
S8698 GLPG1837 <1 mg/mL 69 mg/mL 5 mg/mL
S1565 VX-809 (Lumacaftor) <1 mg/mL 90 mg/mL 6 mg/mL
S7059 Tezacaftor (VX-661) <1 mg/mL 100 mg/mL <1 mg/mL
Catalog No. Information Product Use Citations Product Validations

Ataluren (PTC124)

Ataluren (PTC124) selectively induces ribosomal read-through of premature but not normal termination codons, with EC50 of 0.1 μM in HEK293 cells, may provide treatment for genetic disorders caused by nonsense mutations (e.g. CF caused by CFTR nonsense mutation). Phase 3.



CFTRinh-172 is a voltage-independent, selective CFTR inhibitor with Ki of 300 nM, showing no effects on MDR1, ATP-sensitive K+ channels, or a series of other transporters.



IOWH032 is a synthetic CFTR inhibitor with IC50 of 1.01 μM in CHO-CFTR cell based assays. Phase 2.



GlyH-101 is a selective and reversible CFTR inhibitor with Ki of 4.3 μM.


Ivacaftor (VX-770)

Ivacaftor (VX-770) is a selective potentiator of CFTR targeting G551D-CFTR and F508del-CFTR with EC50 of 100 nM and 25 nM in fisher rat thyroid cells, respectively.



GLPG1837 is a novel CFTR potentiator with an EC50 value of 3 nM for F508del, showing enhanced efficacy on CFTR mutants harboring class III mutations compared to Ivacaftor.


VX-809 (Lumacaftor)

VX-809 (Lumacaftor) acts to correct CFTR mutations common in cystic fibrosis by increasing mutant CFTR (F508del-CFTR) maturation,EC50 of 0.1 μM in fisher rat thyroid cells. Phase 3.


Tezacaftor (VX-661)

Tezacaftor (VX-661) is a second F508del CFTR corrector and is believed to help CFTR protein reach the cell surface. Phase 2.